Some GLP-1s May Lower the Risk of Worsening Mental Health

The GLP-1 receptor agonist is an agent used for the management of type 2 diabetes mellitus and body weight. Examples include semaglutide and liraglutide .Recent studies have revealed that some agents among this class of drug may also be useful in the prevention of mental disorders. Such a development becomes pertinent considering the rising use of GLP-1 drugs recently.

Why It Matters

Medication that affects your appetite and body weight can also affect your mood and general wellbeing. Generally speaking, having good control of blood glucose and being overweight leads to an improvement in how patients generally feel and behave because the patient is experiencing less illnesses and complications. For instance, when someone does not experience hunger and lethargy anymore, he will be motivated to exercise and sleep better, which improves his mood. However, the adverse effects of GLP-1 medications (such as nausea and headaches) might make patients uncomfortable and anxious.

There is evidence from recent research that suggests that some of these GLP-1 drugs may even lower the risk of deteriorating mental health conditions. As an example, one study conducted in Sweden revealed that people receiving semaglutide treatment had up to 40% less risk of worsening depression and anxiety compared to other treatments. Patients on GLP-1 drugs in this particular case were less likely to experience hospitalization or take time off due to mental health concerns. Furthermore, another meta-analysis of many different clinical trials showed that these medications neither caused depression nor increased the risk of suicide. On the contrary, patients felt better overall.

This potential benefit should not be ignored by clinicians and policymakers alike. Physicians deciding on whether to prescribe a patient diabetes medication or one that will aid with weight loss need to consider its impact on their mental well-being together with its heart health and weight loss benefits. In case any of the GLP-1 medications proves to have a beneficial effect on mental health, it may become especially popular among people susceptible to depression and/or anxiety disorders. Insurers and other health care decision makers must realize the importance of their decisions since mandatory prescriptions of a single type of GLP-1 will concentrate the impact of such drugs on vulnerable populations.

There are safety considerations as well as implications over time. Any decrease in the chance of experiencing depression or anxiety, even if it is just a small decrease, can affect the frequency at which a patient must return for a follow-up visit or mental status exam. However, with some uncertainty regarding these implications, patients may be wary as well as prescribers, particularly those with a history of a mental disorder. This is where the guidelines become necessary.

Who It Affects

People suffering from type 2 diabetes and individuals seeking treatment for obesity are the two major populations that currently use GLP-1 medications. However, with these medications becoming common in other settings, such as primary care offices and obesity treatment centers, their population is increasing rapidly. Moreover, many of these individuals tend to suffer from high prevalence of conditions such as anxiety, depression or insomnia. Therefore, any change in mood due to medication in such a person is highly apparent.

On the healthcare side, primary care doctors and endocrinologists write most of the GLP-1 prescriptions. They are on the front lines of observing any mental-health changes. Meanwhile, psychiatrists, therapists and bariatric (weight loss) surgeons increasingly see patients who are also on metabolic medicines. Pharmacists, diabetes educators and nurse practitioners play a role too: they educate patients about side effects, watch for mood changes, and help coordinate care if problems arise.

Insurance companies and health systems have a stake as well. If a payer’s rules mean most patients get one specific GLP-1 drug (for example, because it’s cheaper), then any drug-specific effects on mood or anxiety will affect lots of people. In contrast, if patients and doctors can choose among several GLP-1s, they have a better chance to match the right drug to the person. There are also broader concerns of fairness and access: communities that already struggle to get mental health care might suffer more if a medication worsens mood and they can’t easily see a therapist. Equity matters when we consider such widely used treatments.

What Changes

Experts suggest the following steps to integrate mental health with GLP-1 care:

• Assess each patient’s mental health before starting a GLP-1. Ask about any history of depression, anxiety, or suicidal thoughts, and note their current mood and sleep patterns.
• Follow up early. Schedule a check-in just a few weeks after starting the medication. Ask patients and family members about changes in appetite, energy level, irritability, anxiety or sleep.
• Choose wisely. If a patient has depression or anxiety, consider using a GLP-1 drug that research has shown to have a better track record for mood (for example, semaglutide in some studies). Combine the prescription with behavioral health support like counseling or therapy.
• Monitor mental health in care protocols. Clinics and health systems should add routine mood and anxiety screening to diabetes and weight-loss follow-up visits (for example, using a short questionnaire). Insurers and pharmacies should also recognize that coverage decisions can affect mental health outcomes.
• Train staff. Doctors, nurses and other clinicians who aren’t mental health specialists need training on spotting warning signs (like new sadness or panic) when patients start metabolic treatments. They should know when and how to refer patients to a psychiatrist or counselor.

Clinical Decision-making and Factors Influencing Patient Care Selection of a GLP-1 should be based on a collaborative process that involves physical and psychological aspects. For instance, the physician may note that: “Although this medication will reduce your blood glucose levels and lead to weight loss and, therefore, make you feel better psychologically, any medication has its adverse effects, and I would like to discuss potential impact of this one on your mood and sleep.” If the patient suffers from active depressive disorder, referral to a psychiatrist may be advisable or extremely careful follow-up.

Practical monitoring will be easy. First, record the mood, stress level, and suicidal ideations of the patient prior to commencing on the GLP-1. Afterward, plan an appointment with the patient after a couple of weeks. In the discussion, inquire about his/her appetite, sleep, energy levels, and presence of anxiety and depression. Caregivers and close relatives can be helpful too when determining the presence of such signs. When depressive or anxious symptoms surface, it would be best to reduce the dose, stop the medicine temporarily, or even seek psychiatric evaluation, depending on the severity of the problem.

System-Level and Policy Implications

It would be useful if health systems and policymakers developed better connections between treatments for diabetes and mental health. That may involve facilitating access to psychological assessment when it is required for someone undergoing treatment at a weight loss clinic. Electronic medical records can support such efforts through alerts suggesting a check for symptoms of depression or anxiety during important visits.

On the other hand, insurers should also take mental well-being into account while forming their policies. While making everyone use a particular GLP-1 may appear economically rational on a short-term basis, this approach risks failing in the long run if this GLP-1 causes more psychological side effects than others. Increased insurance coverage giving patients a choice will allow providers to prescribe a medication that works best for an individual.

What Comes Next

Clinically, we should expect new guidance on this topic. Medical societies and health organizations are likely to offer checklists and referral algorithms that help busy clinicians tie together physical and mental health in diabetes care. For example, a family doctor’s checklist might include both blood sugar levels and a quick mood screen at certain visits.

On the research side, studies will continue to follow patients on GLP-1 drugs for longer periods and in real-world settings. Scientists will try to figure out exactly which kinds of patients get mental-health benefits from these medications. Patient registries (where treatment data is linked to health outcomes) could show, over time, whether some people do better on one GLP-1 drug versus another in terms of mood and daily function.

In the meantime, doctors and patients should stay cautiously optimistic. It’s fair to say “Some people feel more energetic and hopeful when they lose weight with these drugs, but let’s keep an eye on how you feel.”

For patients: Talk openly with your doctor about your mental health history. Learn what mood or anxiety symptoms to watch for, and plan a short-term follow-up to review how you’re feeling. Remember, if you notice new sadness or worry after starting a GLP-1, it could be from the medication or just part of adjusting – but in any case, it’s worth discussing.

For healthcare leaders: The message is clear: connect behavioral health and metabolic care. When making coverage decisions, consider the whole patient. Invest in systems (like co-located mental health counselors or tele-psychiatry support) so clinicians can safely prescribe these powerful drugs. By doing so, we can help ensure that any mental health benefits of GLP-1s reach all patients, and that downsides are caught and treated early.

References

1. Karolinska Institutet. Diabetes drug Ozempic linked to better mental health. Karolinska Institutet News. 2026. Available from: Read article [\[news.ki.se\]](https://news.ki.se/diabetes-drug-ozempic-linked-to-better-mental-health)
2. U.S. Food and Drug Administration. Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. FDA Drug Safety Communication. 2024. Available from: Read safety communication [\[fda.gov\]](https://www.fda.gov/drugs/drug-safety-communications/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type)
3. Alansari AO, Alharbi AS, Alshehri KM, et al. Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation. Medicine (Baltimore). 2025. Available from: Read on PubMed Central [\[pmc.ncbi.nlm.nih.gov\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12688971/)
4. American Diabetes Association Professional Practice Committee for Diabetes. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2026. Diabetes Care. 2026. Available from: View guideline [\[diabetesjournals.org\]](https://diabetesjournals.org/care/article/49/Supplement_1/S89/163932/5-Facilitating-Positive-Health-Behaviors-and-Well)